Home ›
Non-Hodgkin Lymphoma Lymphoma Trials ›
NCT05006716
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
Trial Details
NCT ID NCT05006716 Phase PHASE1 / PHASE2
Sponsor BeOne Medicines
Status RECRUITING
Cancer Type Non-Hodgkin Lymphoma Lymphoma
Interventions Locations (sample) Birmingham, Alabama, United States|33.52066,-86.80249 Phoenix, Arizona, United States|33.44838,-112.07404 Scottsdale, Arizona, United States|33.50921,-111.89903 Tucson, Arizona, United States|32.22174,-110.92648 La Jolla, California, United States|32.84727,-117.2742
Key Eligibility Criteria
Confirmed diagnosis (per World Health Organization (WHO) guidelines, unless otherwise noted) of one of the following: Marginal Zone Lymphoma (MZL),… Participants who have previously received a covalently-binding Bruton´s tyrosine kinase (BTK) inhibitor (BTKi) in any line of therapy must have rec… For dose-finding and dose-expansion, participants who had previously received a covalently-binding BTK inhibitor as monotherapy or in combination w… Phase 2 Cohorts in R/R CLL/SLL, R/R MCL, and R/R WM only: Participants who previously received a BTKi are eligible if they had disease progression … For full eligibility, visit ClinicalTrials.gov .